1. Home
  2. PSTV vs INM Comparison

PSTV vs INM Comparison

Compare PSTV & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PLUS THERAPEUTICS Inc.

PSTV

PLUS THERAPEUTICS Inc.

HOLD

Current Price

$0.67

Market Cap

61.1M

Sector

Health Care

ML Signal

HOLD

Logo InMed Pharmaceuticals Inc.

INM

InMed Pharmaceuticals Inc.

HOLD

Current Price

$1.44

Market Cap

3.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSTV
INM
Founded
1996
1981
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.1M
3.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PSTV
INM
Price
$0.67
$1.44
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$7.25
N/A
AVG Volume (30 Days)
6.1M
888.4K
Earning Date
10-30-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,258,000.00
$4,798,116.00
Revenue This Year
$28.21
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$1.13
52 Week High
$2.31
$8.27

Technical Indicators

Market Signals
Indicator
PSTV
INM
Relative Strength Index (RSI) 58.96 46.19
Support Level $0.61 $1.28
Resistance Level $0.70 $1.52
Average True Range (ATR) 0.05 0.11
MACD 0.01 0.03
Stochastic Oscillator 62.10 75.00

Price Performance

Historical Comparison
PSTV
INM

About PSTV PLUS THERAPEUTICS Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

About INM InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.

Share on Social Networks: